Company Description
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder.
It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD.
In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders.
ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
| Country | Germany |
| Founded | 2018 |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Srinivas Rao |
Contact Details
Address: Wallstraße 16 Berlin, 10179 Germany | |
| Phone | 49 89 2153 9035 |
| Website | atai.com |
Stock Details
| Ticker Symbol | ATAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001840904 |
| CUSIP Number | N0731H103 |
| ISIN Number | NL0015000DX5 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Srinivas G. Rao M.D., Ph.D. | Co-Founder, Chief Executive Officer and Executive Director |
| Christian Angermayer | Co-Founder and Chairman of the Supervisory Board |
| Anne Johnson | Chief Financial Officer |
| Dr. Gerd G. Kochendoerfer Ph.D. | Chief Operating Officer |
| Dr. Glenn Short Ph.D. | Chief Scientific Officer |
| Ryan Barrett J.D. | General Counsel and Corporate Secretary |
| Dr. Kevin Craig M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | SCHEDULE 13D/A | Filing |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 14, 2025 | 8-K | Current Report |
| Jul 2, 2025 | 144 | Filing |
| Jul 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 1, 2025 | 144 | Filing |
| Jul 1, 2025 | 8-K | Current Report |
| Jul 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |